Published in EMBO J on May 01, 1990
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci U S A (1994) 3.30
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol (1994) 3.05
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A (1991) 2.86
Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A (1997) 2.80
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol (2001) 2.69
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol (1993) 2.55
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J (1992) 2.45
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A (1998) 2.28
Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci U S A (1995) 2.27
Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A (1991) 2.27
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest (1993) 2.25
p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J (1996) 2.25
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J (1993) 2.21
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol (1991) 2.20
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A (1996) 2.18
p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J (1993) 2.16
Heterochromatin silencing of p53 target genes by a small viral protein. Nature (2010) 2.12
Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res (1992) 2.07
The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A (1993) 2.01
Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci U S A (1991) 1.99
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. EMBO J (1993) 1.78
Li-fraumeni syndrome. Genes Cancer (2011) 1.77
p53 expression in colorectal tumors. Am J Pathol (1991) 1.77
Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A (1999) 1.73
Analysis of p53 mutants for transcriptional activity. Mol Cell Biol (1991) 1.73
Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol Cell (2013) 1.72
Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J (1997) 1.70
Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci U S A (1991) 1.65
p53 is covalently linked to 5.8S rRNA. Mol Cell Biol (1992) 1.65
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol (1996) 1.65
Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J (1994) 1.64
Hsp70 interactions with the p53 tumour suppressor protein. EMBO J (2001) 1.62
Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol Cell Biol (1991) 1.61
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest (1993) 1.57
The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci U S A (1995) 1.52
Decreased UDP-GlcNAc levels abrogate proliferation control in EMeg32-deficient cells. EMBO J (2000) 1.51
A temperature-sensitive mutant of human p53. EMBO J (1994) 1.51
Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J (1992) 1.49
A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res (1991) 1.49
Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev (2000) 1.47
Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer (1992) 1.47
Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer (2011) 1.45
High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol (1996) 1.42
Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J Virol (1992) 1.41
Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium. Br J Ophthalmol (2000) 1.40
Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol Cell Biol (1991) 1.39
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol Cell Biol (1993) 1.38
HEX: a novel homeobox gene expressed during haematopoiesis and conserved between mouse and human. Nucleic Acids Res (1993) 1.38
Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Sci U S A (1996) 1.36
Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia (2006) 1.34
DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J (1995) 1.33
Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. EMBO J (1992) 1.33
p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol (1995) 1.32
Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc Natl Acad Sci U S A (2003) 1.30
Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol (1991) 1.29
Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol (1997) 1.28
Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J (2000) 1.26
Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol (1993) 1.25
Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. Proc Natl Acad Sci U S A (1994) 1.25
Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res (2013) 1.24
The amino-terminal functions of the simian virus 40 large T antigen are required to overcome wild-type p53-mediated growth arrest of cells. J Virol (1994) 1.22
Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer (1993) 1.22
Probing the in vivo function of Mad1:C-Mad2 in the spindle assembly checkpoint. EMBO J (2011) 1.19
Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci U S A (1992) 1.15
Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol (1996) 1.15
Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res (1992) 1.13
Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer (1992) 1.13
The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J (1993) 1.13
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A (1996) 1.13
Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer (2011) 1.12
Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells. EMBO J (1990) 1.12
Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11
The ability of large T antigen to complex with p53 is necessary for the increased life span and partial transformation of human cells by simian virus 40. J Virol (1991) 1.11
Analysis of a protein-binding domain of p53. Mol Cell Biol (1993) 1.10
Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene. Mol Cell Biol (1994) 1.10
Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol (1994) 1.08
Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Mol Cell Biol (1994) 1.08
Nonspecific DNA binding activity of simian virus 40 large T antigen: evidence for the cooperation of two regions for full activity. J Virol (1992) 1.07
The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer (1992) 1.07
A novel function for p53: regulation of growth cone motility through interaction with Rho kinase. J Neurosci (2009) 1.05
Simian virus 40 large T antigen contains two independent activities that cooperate with a ras oncogene to transform rat embryo fibroblasts. J Virol (1995) 1.05
Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours. Gut (1994) 1.04
The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer (1994) 1.04
Specific mismatch recognition in heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination. Mol Cell Biol (1998) 1.04
p53 expression in colorectal adenomas. Am J Pathol (1993) 1.04
Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer (1992) 1.03
p53 is associated with p34cdc2 in transformed cells. EMBO J (1990) 1.03
Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. EMBO J (1994) 1.03
Role of c-myc in simian virus 40 large tumor antigen-induced DNA synthesis in quiescent 3T3-L1 mouse fibroblasts. Proc Natl Acad Sci U S A (1994) 1.03
p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts. J Clin Pathol (1992) 1.02
Isg15 controls p53 stability and functions. Cell Cycle (2014) 1.02
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol (1981) 15.59
Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 14.05
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature (1985) 5.69
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
An immunoaffinity purification procedure for SV40 large T antigen. Virology (1985) 4.81
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
Rapid purification of mammalian 70,000-dalton stress proteins: affinity of the proteins for nucleotides. Mol Cell Biol (1985) 4.75
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol (1989) 4.63
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
P53 expression in breast cancer. Int J Cancer (1988) 3.51
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell (1989) 3.01
Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol (1987) 3.01
Precise epitope mapping of the murine transformation-associated protein, p53. EMBO J (1985) 2.98
Mouse p53 inhibits SV40 origin-dependent DNA replication. Nature (1987) 2.71
Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene (1988) 2.53
Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (1987) 2.50
Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene (1987) 2.26
Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci U S A (1989) 2.14
Expression of the nuclear oncogene p53 in colon tumours. J Pathol (1989) 2.05
Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. Oncogene (1988) 1.96
Allele loss on short arm of chromosome 17 in breast cancers. Lancet (1988) 1.86
Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology (1983) 1.78
Mouse p53 blocks SV40 DNA replication in vitro and downregulates T antigen DNA helicase activity. Oncogene (1988) 1.53
Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol Cell Biol (1988) 1.48
A modified method to induce immune polyclonal ascites fluid in BALB/c mice using Sp2/0-Ag14 cells. J Immunol Methods (1986) 1.37
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Cancer. p53, guardian of the genome. Nature (1992) 16.36
Regulation of the specific DNA binding function of p53. Cell (1992) 6.16
Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell (1985) 5.88
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
An immunoaffinity purification procedure for SV40 large T antigen. Virology (1985) 4.81
Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell (1993) 4.62
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 3.89
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49
SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature (1980) 3.44
Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci (1990) 3.35
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res (1994) 3.28
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods (1992) 3.23
High levels of p53 protein in UV-irradiated normal human skin. Oncogene (1993) 3.15
Using the polymerase chain reaction to modify expression plasmids for epitope mapping. Nucleic Acids Res (1989) 3.15
Two pathways for base excision repair in mammalian cells. J Biol Chem (1996) 3.01
Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 2.96
Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A (1997) 2.90
Requirement for the replication protein SSB in human DNA excision repair. Nature (1991) 2.80
Nuclear protein with sequence homology to translation initiation factor eIF-4A. Nature (1988) 2.77
Use of monoclonal antibodies as probes of simian virus 40 T antigen ATPase activity. J Biol Chem (1981) 2.77
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 2.75
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol (1995) 2.57
An immunochemical investigation of SV40 T antigens. 1. Production properties and specificity of rabbit antibody to purified simian virus 40 large-T antigen. Virology (1978) 2.49
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene (1991) 2.42
p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol (1994) 2.41
Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet (1993) 2.40
Structure and function of SV40 large-T antigen. Philos Trans R Soc Lond B Biol Sci (1987) 2.37
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A (1998) 2.28
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep (2001) 2.27
Allosteric activation of latent p53 tetramers. Curr Biol (1994) 2.25
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol (1997) 2.25
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene (2001) 2.14
Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res (1992) 2.07
DbpA: a DEAD box protein specifically activated by 23s rRNA. EMBO J (1993) 2.04
Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature (1991) 1.99
Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene (1999) 1.98
Nuclear protein p68 is an RNA-dependent ATPase. EMBO J (1989) 1.98
p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet (1991) 1.95
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. Nucleic Acids Res (1992) 1.91
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology (1983) 1.78
Origins of the prestalk-prespore pattern in Dictyostelium development. Cell (1989) 1.78
Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays (1995) 1.75
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol (1995) 1.75
Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene (1996) 1.75
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res (1999) 1.74
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res (2001) 1.73
Cancer. A death in the life of p53. Nature (1993) 1.70
The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays (1993) 1.70
p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts. Mol Cell Biol (1991) 1.69
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer (1990) 1.69
Isolation and analysis of the fission yeast gene encoding polymerase delta accessory protein PCNA. EMBO J (1992) 1.68
Molecular characterization of the hdm2-p53 interaction. J Mol Biol (1997) 1.64
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol (1992) 1.62
Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci (1995) 1.57
Effects of maternal tobacco smoking, sleeping position, and sleep state on arousal in healthy term infants. Arch Dis Child Fetal Neonatal Ed (2002) 1.53
Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet (1992) 1.53
Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A (2000) 1.52
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene (1995) 1.51
Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res (1993) 1.49
A rapid PCR fidelity assay. Nucleic Acids Res (1994) 1.47
Ku selectively transfers between DNA molecules with homologous ends. J Biol Chem (1997) 1.46
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol (1991) 1.46
Transcriptional activation by the acidic domain of Vmw65 requires the integrity of the domain and involves additional determinants distinct from those necessary for TFIIB binding. Mol Cell Biol (1993) 1.46
The p53 response to ionising radiation in adult and developing murine tissues. Oncogene (1996) 1.46
APC expression in normal human tissues. J Pathol (1997) 1.44
Increased apoptosis induction by 121F mutant p53. EMBO J (1999) 1.41
The complex between simian virus 40 T antigen and a specific host protein. Proc R Soc Lond B Biol Sci (1980) 1.41
Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene (1991) 1.40
Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell (1992) 1.39
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
Identification of novel mdm2 binding peptides by phage display. Oncogene (1996) 1.37
Interference with the assembly of a virus-host transcription complex by peptide competition. Nature (1990) 1.37
Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 1.37
The p53 tumour suppressor gene. Br J Surg (1998) 1.37
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ (2010) 1.36
Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene (1991) 1.36
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ (2010) 1.35
C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene (2012) 1.35
p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene (1995) 1.34
p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res (1993) 1.34
Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair. Oncogene (1997) 1.34
PCNA binding proteins in Drosophila melanogaster : the analysis of a conserved PCNA binding domain. Nucleic Acids Res (1998) 1.32
Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. Oncogene (1991) 1.32
Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene (1999) 1.30
Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology (1992) 1.30
p53 expression and prognosis in gastric carcinoma. Int J Cancer (1992) 1.29